Coherus Oncology, Inc.
CHRS
$0.7472
-$0.0204-2.66%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.60M | 54.14M | 70.77M | 64.98M | 2.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.60M | 54.14M | 70.77M | 64.98M | 2.31M |
| Cost of Revenue | 2.65M | 33.86M | 20.74M | 28.37M | 1.44M |
| Gross Profit | 4.95M | 20.29M | 50.03M | 36.61M | 869.00K |
| SG&A Expenses | 26.03M | 34.60M | 34.74M | 35.17M | 29.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.03M | 89.69M | 77.16M | 85.49M | 59.50M |
| Operating Income | -45.44M | -35.55M | -6.39M | -20.51M | -57.19M |
| Income Before Tax | -47.40M | -50.70M | -10.75M | -12.92M | -68.04M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -47.40M | -50.70M | -10.75M | -12.92M | -68.04M |
| Earnings from Discontinued Operations | -9.17M | -- | -- | -- | 170.91M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.57M | -50.70M | -10.75M | -12.92M | 102.88M |
| EBIT | -45.44M | -35.55M | -6.39M | -20.51M | -57.19M |
| EBITDA | -44.39M | -34.51M | -4.84M | -19.32M | -55.68M |
| EPS Basic | -0.49 | -0.44 | -0.09 | -0.11 | 0.91 |
| Normalized Basic EPS | -0.26 | -1.19 | -0.06 | 0.00 | -0.32 |
| EPS Diluted | -0.49 | -0.47 | -0.09 | -0.11 | 0.91 |
| Normalized Diluted EPS | -0.26 | -1.19 | -0.06 | 0.00 | -0.32 |
| Average Basic Shares Outstanding | 115.86M | 115.42M | 115.21M | 114.82M | 112.75M |
| Average Diluted Shares Outstanding | 115.86M | 115.42M | 115.21M | 114.82M | 112.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |